ProfileGDS5678 / 1437922_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 5% 5% 5% 5% 5% 5% 5% 5% 5% 5% 5% 5% 5% 5% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.075625
GSM967853U87-EV human glioblastoma xenograft - Control 22.058625
GSM967854U87-EV human glioblastoma xenograft - Control 32.059855
GSM967855U87-EV human glioblastoma xenograft - Control 42.024695
GSM967856U87-EV human glioblastoma xenograft - Control 52.016285
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.136225
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.064775
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.038925
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.038895
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.04715
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.043885
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.038095
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.047265
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.051285